Clinical Trials · NCT02217826
Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Aspireo Pharmaceuticals Limited
- Enrollment
- 8
- Start date
- Not specified
- Locations
- See registry
- Primary endpoint
- Concentration of glucose, insulin and glucagon in plasma.